Drugtrend-agegen5rev2

DTR03-covtabs Production Final 5/19/04 4:15 PM Page 13 AGE AND GENDER APPENDIX
5 AGE AND GENDERAPPENDIX
E X P R E S S S C R I P T S D R U G T R E N D R E P O R T
drugtrend-agegen5rev2 5/19/04 4:30 PM Page 143 AGE AND GENDER APPENDIX
Drug Prevalence by Age and Gender
This appendix to the 2003 Drug Trend Report presents the prevalence ofuse by age and gender for the top 25 therapy classes ranked by cost. Thesample of members used to determine prevalence and to create these chartswas the same sample of 2.1 million members whose prescription use wasanalyzed to determine overall trend from 2002 to 2003. These membersbelonged to groups offering a funded benefit that allowed members touse either retail or mail pharmacies. Members belonging to groups withMedicare or Medicaid benefits were excluded. For the purpose of this appendix, prevalence was defined as the percentageof eligible members who filled at least one prescription in the therapyclass during 2003. Age was determined by the member’s age on the lastday of 2003.
Antihyperlipidemics
Prevalence of Use by Age and Gender 2003
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 drugtrend-agegen5rev2 5/19/04 4:30 PM Page 144 AGE AND GENDER APPENDIX
Gastrointestinals
Antihypertensives
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
AGE AND GENDER APPENDIX
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 Antidepressants
Anti-Rheumatics (NSAIDs)
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 144 express scripts drug trend report 2003
drugtrend-agegen5rev2 5/19/04 4:30 PM Page 146 AGE AND GENDER APPENDIX
Antidiabetics
Miscellaneous Endocrines
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
AGE AND GENDER APPENDIX
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 Antiasthmatics
Narcotic Analgesics
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 146 express scripts drug trend report 2003
drugtrend-agegen5rev2 5/19/04 4:30 PM Page 148 AGE AND GENDER APPENDIX
Anticonvulsants
Dermatologicals
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
AGE AND GENDER APPENDIX
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 Antivirals
Antihistamines
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 148 express scripts drug trend report 2003
drugtrend-agegen5rev2 5/19/04 4:30 PM Page 150 AGE AND GENDER APPENDIX
Calcium Blockers
Oral Contraceptives
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age 2003
AGE AND GENDER APPENDIX
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 Beta Blockers
Miscellaneous CNS Agents
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 150 express scripts drug trend report 2003
drugtrend-agegen5rev2 5/19/04 4:30 PM Page 152 AGE AND GENDER APPENDIX
Antineoplastics
Quinolones
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
AGE AND GENDER APPENDIX
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 Decongestants
Antipsychotics
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 152 express scripts drug trend report 2003
drugtrend-agegen5rev2 5/19/04 4:30 PM Page 154 AGE AND GENDER APPENDIX
Migraine Products
Macrolides
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age and Gender 2003
AGE AND GENDER APPENDIX
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 Stimulants/Anti-Obesity
Estrogens
Prevalence of Use by Age and Gender 2003
Prevalence of Use by Age 2003
0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 0-4 10-14 20-24 30-34 40-44 50-54 60-64 70-74 80-84 154 express scripts drug trend report 2003
drugtrend-agegen5rev2 5/19/04 4:30 PM Page 156 Notes
AGE AND GENDER APPENDIX
156 express scripts drug trend report 2003

Source: http://esrx.com/research/research/dtr/archive/2003/age_gender.pdf

tagesklinik-bern.ch

Weitere Fragen? Wir hoffen, Ihnen vorerst alle notwendigen Informationen gegeben zu haben. Vor der eigentlichen Operation ergibt sich noch die Gelegenheit zu einem persönlichen Gespräch. Information zur Kataraktoperation Sollten immer noch Fragen oder Unsicherheiten bestehen, die Sie zuvor klären möchten, zögern Sie bitte nicht, mit uns Kontakt aufzunehmen. Sie erreichen uns in

Parasite

Parasite Consequence if left untreated / Clinical Diagnosis Treatment The majority of infections with A. lumbricoides are asymptomatic, and symptoms are largely restricted to individuals with a high worm load Adult worms do not multiply in the human host, so the number of adult worms per infected person relates to the degree of continued exposure to infectious eggs over time. Unt

Copyright © 2010-2014 Drug Shortages pdf